Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. Capricor ( ) is a biotechnology company developing transformative therapeutics for diseases.

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product is a cell therapy designed to treat Duchenne muscular dy

strophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions.

Today, we join the global community in recognizing World Duchenne Awareness Day. This year’s theme, “Access Changes Live...
09/07/2026

Today, we join the global community in recognizing World Duchenne Awareness Day. This year’s theme, “Access Changes Lives,” reminds us that meaningful progress goes beyond just scientific breakthroughs. It means ensuring that individuals living with Duchenne and Becker muscular dystrophy have access to the care, support, and opportunities they need. At Capricor, we remain committed to continuing to push forward with Deramiocel and our mission to help make a difference in the lives of those living with DMD. Together, we can raise awareness, inspire action, and work toward a brighter future for the Duchenne community. 💚

Today we announced that the U.S. FDA has extended the PDUFA target action date for Deramiocel in Duchenne muscular dystr...
08/24/2026

Today we announced that the U.S. FDA has extended the PDUFA target action date for Deramiocel in Duchenne muscular dystrophy to Nov. 22, 2026. The BLA remains under active review. We remain hopeful and focused on bringing Deramiocel to the Duchenne community.
Read the announcement: https://bit.ly/4y2cfQ8

Capricor’s second quarter earnings call is about to begin! Tune in now to hear the latest company updates and financial ...
08/13/2026

Capricor’s second quarter earnings call is about to begin! Tune in now to hear the latest company updates and financial results.
Click the link to access the webcast: https://bit.ly/4c8FCrl

Capricor has just reported its second quarter 2026 financial results and provided a recent corporate update. Click here ...
08/13/2026

Capricor has just reported its second quarter 2026 financial results and provided a recent corporate update. Click here to read the full release: https://bit.ly/4xFcWP4

Capricor will report our second quarter 2026 financial results and provide a corporate update on August 13 at 4:30 p.m. ...
08/10/2026

Capricor will report our second quarter 2026 financial results and provide a corporate update on August 13 at 4:30 p.m. ET. Click here to join the webcast: https://bit.ly/4c8FCrl

Capricor has shared its comments regarding the FDA briefing materials in advance of the upcoming July 29 FDA Advisory Co...
07/27/2026

Capricor has shared its comments regarding the FDA briefing materials in advance of the upcoming July 29 FDA Advisory Committee Meeting for Deramiocel.

Click the link below to read the press release.>>> https://bit.ly/4vRqq96

Today, Our CEO Linda Marbán presented at the Oppenheimer CNS & NeuroMuscular Summit in Miami, Florida, alongside leaders...
06/10/2026

Today, Our CEO Linda Marbán presented at the Oppenheimer CNS & NeuroMuscular Summit in Miami, Florida, alongside leaders from Sarepta and Dyne during the “Advancing Duchenne: Perspectives From Industry Leaders” panel. Proud to be part of the important conversations shaping the future of Duchenne muscular dystrophy treatment and innovation.

Capricor will be participating in two investor conferences this week in Miami — the Goldman Sachs 47th Annual Global Hea...
06/08/2026

Capricor will be participating in two investor conferences this week in Miami — the Goldman Sachs 47th Annual Global Healthcare Conference (fireside chat, June 10 at 10:00 a.m. ET) and the Oppenheimer CNS and Neuro-Muscular Summit.
To view the Goldman Sachs webcast, click here. https://bit.ly/3POYzHT

We are pleased to welcome Michael Maurer to Capricor as our Chief Commercial Officer. With more than two decades of rare...
05/29/2026

We are pleased to welcome Michael Maurer to Capricor as our Chief Commercial Officer. With more than two decades of rare disease commercialization experience across neuromuscular disorders, neuroscience, and immunology, Michael's deep expertise bringing complex therapies to patients further strengthens our team as we prepare for the potential launch of Deramiocel for Duchenne muscular dystrophy and work toward our August 22 PDUFA date. Click here to read the announcement https://bit.ly/3RFEyUw

Address

10865 Road To The Cure
San Diego, CA
92121

Website

Alerts

Be the first to know and let us send you an email when Capricor Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Capricor Therapeutics, Inc.:

Shortcuts

Share

Category